Tandem Diabetes Care, Inc., a medical device company, designs, develops, and markets various products for people with insulin-dependent diabetes in the United States. The company is headquartered in San Diego, California.
| Revenue (TTM) | $1.04B |
| Gross Profit (TTM) | $583.32M |
| EBITDA | $-25.03M |
| Operating Margin | -5.42% |
| Return on Equity | -48.00% |
| Return on Assets | -2.65% |
| Revenue/Share (TTM) | $15.25 |
| Book Value | $1.88 |
| Price-to-Book | 8.74 |
| Price-to-Sales (TTM) | 1.05 |
| EV/Revenue | 1.366 |
| EV/EBITDA | 345.75 |
| Quarterly Earnings Growth (YoY) | -37.00% |
| Quarterly Revenue Growth (YoY) | 5.80% |
| Shares Outstanding | $69.58M |
| Float | $63.76M |
| % Insiders | 1.17% |
| % Institutions | 115.72% |
Volatility is currently expanding
Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
TNDM's expanding pump lineup and pay-as-you-go model support growth prospects, though macro and competitive pressures remain.
Tandem Diabetes Care NASDAQ: TNDM highlighted its plans to expand insulin pump adoption through a shift to pharmacy distribution in the U.S., direct sales in additional international markets and upcoming product launches, including a tubeless version of its Tandem Mobi pump.
Tandem Diabetes shares jump 19.1% after a narrower-than-expected Q2 loss, as higher pump shipments and a 57% gross margin offset a slight revenue miss.
Tandem Diabetes Care NASDAQ: TNDM reported second-quarter results that included record sales, pump shipments and gross margin for a second quarter, while management highlighted early progress in its transition to pharmacy-channel reimbursement and continued development of new insulin-delivery technologies.
Tandem Diabetes Care, Inc. (TNDM) Q2 2026 Earnings Call Transcript
Tandem Diabetes Care, Inc. TNDM is well-poised to grow in the coming quarters as the rising prevalence of diabetes and increasing adoption of connected care continue to support demand for automated insulin delivery. The company's pay-as-you-go reimbursement model could lower upfront barriers for pump starts and support higher supply revenue per customer over time.
SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--The t:slim X2™ insulin pump from Tandem Diabetes Care is now compatible with Abbott's FreeStyle Libre 3 Plus CGM sensor in five EU countries.
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2026 results after the financial markets close on Thursday, August 6, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2026 financial and operating results.A live webcast of the call will be available on Tandem Diabet.
The average of price targets set by Wall Street analysts indicates a potential upside of 56.2% in Tandem Diabetes Care (TNDM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TNDM and any ticker you trade — then tracks every position and per-strategy win rate.
